Aingle-angel oral etoposide in patients with relapsed or refractory extensive small-cell lung cancer
Küçük Resim Yok
Tarih
2002
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Objective: To evaluate the effectiveness and toxicity of prolonged low-dose oral etoposide in patients with relapsed or refrac-tory extensive small-cell lung cancer. Patients and Design: Thirty-one patients with relapsed or refractory extensive SCLC were treated with oral etoposide 50 mg (25 mg bid) for 14 days every 3 weeks. Response, duration of response, survival and toxicity were evaluated. Setting: Departments of Pulmonary Medicine and Medical Oncology, School of Medicine, Ege University. Complete response was not observed. Median duration of response was 16 weeks. Median survival was 16 weeks (range, 4-48 weeks). Two patients developed grade 3 leukopenia and 6 had grade 1-2 leukopenia. Two patients had grade 1-2 thrombocytopenia One patient developed grade 2 nausea/vomiting, and one patient grade 2 diarrhea. Conclusion: Prolonged administration of low-dose oral etoposide is well tolerated in relapsed or refractory SCLC and has thera-peutic efficacy.
Objective: To evaluate the effectiveness and toxicity of prolonged low-dose oral etoposide in patients with relapsed or refrac-tory extensive small-cell lung cancer. Patients and Design: Thirty-one patients with relapsed or refractory extensive SCLC were treated with oral etoposide 50 mg (25 mg bid) for 14 days every 3 weeks. Response, duration of response, survival and toxicity were evaluated. Setting: Departments of Pulmonary Medicine and Medical Oncology, School of Medicine, Ege University. Complete response was not observed. Median duration of response was 16 weeks. Median survival was 16 weeks (range, 4-48 weeks). Two patients developed grade 3 leukopenia and 6 had grade 1-2 leukopenia. Two patients had grade 1-2 thrombocytopenia One patient developed grade 2 nausea/vomiting, and one patient grade 2 diarrhea. Conclusion: Prolonged administration of low-dose oral etoposide is well tolerated in relapsed or refractory SCLC and has thera-peutic efficacy.
Objective: To evaluate the effectiveness and toxicity of prolonged low-dose oral etoposide in patients with relapsed or refrac-tory extensive small-cell lung cancer. Patients and Design: Thirty-one patients with relapsed or refractory extensive SCLC were treated with oral etoposide 50 mg (25 mg bid) for 14 days every 3 weeks. Response, duration of response, survival and toxicity were evaluated. Setting: Departments of Pulmonary Medicine and Medical Oncology, School of Medicine, Ege University. Complete response was not observed. Median duration of response was 16 weeks. Median survival was 16 weeks (range, 4-48 weeks). Two patients developed grade 3 leukopenia and 6 had grade 1-2 leukopenia. Two patients had grade 1-2 thrombocytopenia One patient developed grade 2 nausea/vomiting, and one patient grade 2 diarrhea. Conclusion: Prolonged administration of low-dose oral etoposide is well tolerated in relapsed or refractory SCLC and has thera-peutic efficacy.
Açıklama
Anahtar Kelimeler
Solunum Sistemi
Kaynak
Turkish Respiratory Journal
WoS Q Değeri
Scopus Q Değeri
Cilt
3
Sayı
1